Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II clinical study of AL001, in healthy human subjects.

Next Previous
Trial Profile

A Phase II clinical study of AL001, in healthy human subjects.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lithium cocrystal Alzamend Neuro (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics; Therapeutic Use

Most Recent Events

  • 16 Jun 2025 According to the Alzamend Neuro media release, the company announced $5 million in gross proceeds from this Financing received, The capital raised will be used to support the five Phase II clinical trials of AL001 "Lithium in Brain" Studies at Massachusetts General Hospital.
  • 23 May 2025 New trial record
  • 19 May 2025 According to the Alzamend Neuro media release, company announced the enrollment of the first patient of its first Phase II clinical study of AL001, in healthy human subjects. topline data anticipated by the end of the year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top